SG11202106965RA - Substituted polycyclic carboxylic acids, analogues thereof, and methods using same - Google Patents

Substituted polycyclic carboxylic acids, analogues thereof, and methods using same

Info

Publication number
SG11202106965RA
SG11202106965RA SG11202106965RA SG11202106965RA SG11202106965RA SG 11202106965R A SG11202106965R A SG 11202106965RA SG 11202106965R A SG11202106965R A SG 11202106965RA SG 11202106965R A SG11202106965R A SG 11202106965RA SG 11202106965R A SG11202106965R A SG 11202106965RA
Authority
SG
Singapore
Prior art keywords
analogues
methods
same
carboxylic acids
substituted polycyclic
Prior art date
Application number
SG11202106965RA
Inventor
Shuai Chen
Andrew G Cole
Bruce D Dorsey
Yi Fan
Dimitar B Gotchev
Ramesh Kakarla
Sharon Marie Kirk
Jorge Quintero
Michael J Sofia
Original Assignee
Arbutus Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corp filed Critical Arbutus Biopharma Corp
Publication of SG11202106965RA publication Critical patent/SG11202106965RA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202106965RA 2019-01-17 2020-01-15 Substituted polycyclic carboxylic acids, analogues thereof, and methods using same SG11202106965RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962793578P 2019-01-17 2019-01-17
PCT/US2020/013701 WO2020150366A1 (en) 2019-01-17 2020-01-15 Substituted polycyclic carboxylic acids, analogues thereof, and methods using same

Publications (1)

Publication Number Publication Date
SG11202106965RA true SG11202106965RA (en) 2021-08-30

Family

ID=71613992

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202106965RA SG11202106965RA (en) 2019-01-17 2020-01-15 Substituted polycyclic carboxylic acids, analogues thereof, and methods using same

Country Status (14)

Country Link
US (1) US20220125771A1 (en)
EP (1) EP3911653A4 (en)
JP (1) JP2022518456A (en)
KR (1) KR20210121044A (en)
CN (1) CN113825756A (en)
AU (1) AU2020208371A1 (en)
BR (1) BR112021014079A2 (en)
CA (1) CA3126102A1 (en)
EA (1) EA202191967A1 (en)
IL (1) IL284845A (en)
MX (1) MX2021008646A (en)
SG (1) SG11202106965RA (en)
TW (1) TW202033523A (en)
WO (1) WO2020150366A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI801517B (en) 2018-03-12 2023-05-11 加拿大商愛彼特生物製藥公司 Substituted 2-pyridone tricyclic compounds, analogues thereof, and methods using same
MX2021003253A (en) 2018-09-21 2021-08-11 Enanta Pharm Inc Functionalized heterocycles as antiviral agents.
EP3856740A4 (en) 2018-09-30 2021-12-15 Sunshine Lake Pharma Co., Ltd. Fused tetracyclic compounds and uses thereof in medicine
AU2019385477A1 (en) 2018-11-21 2021-06-10 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
WO2021007488A1 (en) 2019-07-11 2021-01-14 Enanta Pharmaceuticals, Inc. Substituted heterocycles as antiviral agents
US11236108B2 (en) * 2019-09-17 2022-02-01 Enanta Pharmaceuticals, Inc. Functionalized heterocycles as antiviral agents
US11802125B2 (en) 2020-03-16 2023-10-31 Enanta Pharmaceuticals, Inc. Functionalized heterocyclic compounds as antiviral agents
TW202304914A (en) * 2021-04-05 2023-02-01 加拿大商愛彼特生物製藥公司 Substituted tetracyclic carboxylic acids, analogues thereof, and methods using same
WO2024038357A1 (en) * 2022-08-16 2024-02-22 Arbutus Biopharma Corporation Synthesis of substituted tetracyclic carboxylic acids and analogues thereof
CN115819200B (en) * 2022-11-28 2023-08-29 辽宁科技学院 Synthesis method of acenaphthoquinone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA111756C2 (en) * 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг HETEROARYLPYRIDONE AND AZAPIRIDONE COMPOUNDS AS BRUTON TYROSINKINASE INHIBITORS
WO2014121416A1 (en) * 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
CN107820496B (en) * 2015-07-27 2020-11-03 豪夫迈·罗氏有限公司 Tetracyclic 4-oxo-pyridine-3-carboxylic acid derivatives for the treatment and prevention of hepatitis B virus infections
EA038098B1 (en) * 2016-02-19 2021-07-06 Новартис Аг Tetracyclic pyridone compounds as antivirals
WO2018073753A1 (en) * 2016-10-18 2018-04-26 Novartis Ag Fused tetracyclic pyridone compounds as antivirals
AR111419A1 (en) * 2017-04-27 2019-07-10 Novartis Ag INDAZOL PIRIDONA FUSIONED COMPOUNDS AS ANTIVIRALS
CN110066278B (en) * 2017-06-01 2021-06-08 广东东阳光药业有限公司 Fused tricyclic compound and application thereof in medicines

Also Published As

Publication number Publication date
AU2020208371A1 (en) 2021-07-15
CA3126102A1 (en) 2020-07-23
EP3911653A1 (en) 2021-11-24
KR20210121044A (en) 2021-10-07
IL284845A (en) 2021-08-31
CN113825756A (en) 2021-12-21
MX2021008646A (en) 2021-10-26
EA202191967A1 (en) 2021-10-07
JP2022518456A (en) 2022-03-15
BR112021014079A2 (en) 2021-09-21
WO2020150366A1 (en) 2020-07-23
EP3911653A4 (en) 2022-11-02
US20220125771A1 (en) 2022-04-28
TW202033523A (en) 2020-09-16

Similar Documents

Publication Publication Date Title
IL284845A (en) Substituted polycyclic carboxylic acids, analogues thereof, and methods using same
EP3751909A4 (en) Upf selection method and device
HK1253322A1 (en) 3-alkyl-4-amido-bicyclic [4,5,0] hydroxamic acids as hdac inhibitors
EP3585364A4 (en) Particle-drop structures and methods for making and using the same
SG11201702275PA (en) Plasticizer composition which comprises cycloalkyl esters of saturated dicarboxylic acids and 1,2-cyclohexanedicarboxylic esters
SG11201912130RA (en) Novel aspartokinase variant and method for producing l-amino acid using the same
EP3488436A4 (en) Emission-control circuit, display apparatus having the same, and driving method thereof
SG11202001730TA (en) A novel promoter and a method for producing l-amino acid using the same
ZA201906079B (en) Novel ester compounds, method for the production thereof and use thereof
ZA201905065B (en) Novel ester compounds, method for the production thereof and use thereof
IL283395A (en) Substituted arylmethylureas and heteroarylmethylureas, analogues thereof, and methods using same
ZA202001382B (en) Novel promoter and l-amino acid production method using same
SG11202001361XA (en) Microorganism for producing a mycosporine-like amino acid and method for producing a mycosporine-like amino acid using the same
EP3585212A4 (en) Head support and method of using the same
IL285852A (en) Aniline-based wdr5 protein-protein interaction inhibitor, method for preparing the same, and use thereof
EP3153495A4 (en) Method for producing carboxylic acid anhydride, and method for producing carboxylic acid ester
EP3768266A4 (en) Oxo-tetrahydro-isoquinoline carboxylic acids as sting inhibitors
EP3550466C0 (en) Puf-film and method for producing the same
EP4049994A4 (en) Ester compound and preparation method therefor and uses thereof
EP3623360A4 (en) Production method for 1 amino cyclopropane carboxylic acid nonhydrate
GB201919268D0 (en) Methods and compositions comprising carboxylic acids
ZA202003036B (en) Low/medium-carbon ferromanganese production method
EP3682994A4 (en) Apparatus for processing anchor bolt
EP3636630A4 (en) Production method for 1 amino cyclopropane carboxylic acid nonhydrate
EP3638798A4 (en) Nanoneedle and related apparatus and methods